---
title: "Third Harmonic Bio Initiates Strategic Review, Lays Off 50% Staff Citing Competitive Landscape"
date: "2025-02-13 05:41:39"
summary: "Third Harmonic Bio plans a Phase 2 trial for THB335 in chronic spontaneous urticaria and will reduce its workforce by 50% while reviewing strategic options."
categories:
  - "benzinga"
lang:
  - "en"
translations:
  - "en"
tags:
  - "benzinga"
menu: ""
thumbnail: "https://www.benzinga.com/files/images/story/2025/02/12/THRD.png"
lead: ""
comments: false
authorbox: false
pager: true
toc: false
mathjax: false
sidebar: "right"
widgets:
  - "search"
  - "recent"
  - "taglist"
---

Third Harmonic Bio plans a Phase 2 trial for THB335 in chronic spontaneous urticaria and will reduce its workforce by 50% while reviewing strategic options.

[benzinga](https://www.benzinga.com/general/biotech/25/02/43676723/third-harmonic-bio-initiates-strategic-review-lays-off-50-staff-citing-competitive-landscape)
